Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Independent Director 2025 Annual Performance Report
To the shareholders and shareholder representatives:
As an incumbent independent director of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. (hereinafter referred to as "Asia-Pacific Pharmaceutical" or "the Company") for the year 2025, I have strictly adhered to the requirements of relevant laws and regulations such as the "Company Law," "Securities Law," "Management Measures for Independent Directors of Listed Companies," "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guide No. 1 - Norms for Operation of Main Board Listed Companies," and the "Company Articles of Association," and the "Independent Director Work System." I have diligently performed my duties as an independent director, actively attended relevant meetings, listened to reports on the company's production and operation, paid attention to financial status and corporate governance, ensured the independence of my duties, and effectively protected the legitimate rights and interests of the Company and all shareholders, especially small shareholders. Here is my performance report for 2025:
I. Basic Information of Independent Director
Mr. Lv Haizhou, born in January 1975, is a Chinese national with a master's degree and is a certified public accountant. He has served as a clerk at the Shandong Maritime Bureau, Investment Director at Jidong Group Co., Ltd., Editor and Chief Financial Officer at Modern Times Daily, Financial Controller at Oulin Group Co., Ltd., Vice President at Youjiu (Suzhou) Information Technology Co., Ltd., Vice President at Shanghai Lingyue Venture Capital Center (Limited Partnership), and currently serves as Deputy General Manager of Hangzhou Aomo Pharmaceutical Co., Ltd., and Independent Director of Ningbo Oulin Technology Co., Ltd. He served as an independent director of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. from April 2022 to February 2026.